** Shares of drug developer Scholar Rock SRRK.O rise 6.2% to $46.16 premarket

** SRRK, in its earnings release, says it plans to resubmit application to market its experimental drug, apitegromab, to treat muscle disorder known as spinal muscular atrophy $(SMA)$

** Company says the move follows meeting with U.S. FDA and Catalent's Indiana facility, after which the regulator determined that no further action was required

** Apitegromab was previously declined approval in U.S. after drug regulator found issues arising from routine inspection of Catalent's Indiana fill-finish facility, which is owned by Novo Nordisk NOVOb.CO

** SRRK is banking on apitegromab to drive its growth and profitability

** The drug is also being tested for muscle preservation in obesity

** As of last close, SRRK stock was down 1.3% YTD

(Reporting by Padmanabhan Ananthan)

((Padmanabhan.Ananthan@thomsonreuters.com))